Chemistry

Biochemistry

Enzyme

Ejection fraction

Cardiology

Internal medicine

Heart failure

Neprilysin

Medicine

New England Journal of Medicine

The angiotensin receptor–neprilysin inhibitor sacubitril–valsartan led to a reduced risk of hospitalization for heart failure or death from cardiovascular causes among patients with heart failure and reduced ejection fraction. The effect of angiotensin receptor–neprilysin inhibition in patients with heart failure with preserved ejection fraction is unclear.

Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction